Research ExplorerPublicationsCharacteristics and outcomes of patients with atrial versus ...

Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry

Standard

Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry. / Russo, Giulio; Badano, Luigi P; Adamo, Marianna; Alessandrini, Hannes; Andreas, Martin; Braun, Daniel; Connelly, Kim A; Denti, Paolo; Estevez-Loureiro, Rodrigo; Fam, Neil; Gavazzoni, Mara; Hahn, Rebecca T; Harr, Claudia; Hausleiter, Joerg; Himbert, Dominique; Kalbacher, Daniel; Ho, Edwin; Latib, Azeem; Lubos, Edith; Ludwig, Sebastian; Lurz, Philipp; Monivas, Vanessa; Nickenig, Georg; Pedicino, Daniela; Pedrazzini, Giovanni; Pozzoli, Alberto; Pires Marafon, Denise; Pastorino, Roberta; Praz, Fabien; Rodes-Cabau, Joseph; Besler, Christian; Schofer, Joachim; Scotti, Andrea; Piayda, Kerstin; Sievert, Horst; Tang, Gilbert H L; Thiele, Holger; Schlotter, Florian; von Bardeleben, Ralph Stephan; Webb, John; Windecker, Stephan; Leon, Martin; Maisano, Francesco; Metra, Marco; Taramasso, Maurizio.

In: EUR J HEART FAIL, Vol. 25, No. 12, 12.2023, p. 2243-2251.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Russo, G, Badano, LP, Adamo, M, Alessandrini, H, Andreas, M, Braun, D, Connelly, KA, Denti, P, Estevez-Loureiro, R, Fam, N, Gavazzoni, M, Hahn, RT, Harr, C, Hausleiter, J, Himbert, D, Kalbacher, D, Ho, E, Latib, A, Lubos, E, Ludwig, S, Lurz, P, Monivas, V, Nickenig, G, Pedicino, D, Pedrazzini, G, Pozzoli, A, Pires Marafon, D, Pastorino, R, Praz, F, Rodes-Cabau, J, Besler, C, Schofer, J, Scotti, A, Piayda, K, Sievert, H, Tang, GHL, Thiele, H, Schlotter, F, von Bardeleben, RS, Webb, J, Windecker, S, Leon, M, Maisano, F, Metra, M & Taramasso, M 2023, 'Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry', EUR J HEART FAIL, vol. 25, no. 12, pp. 2243-2251. https://doi.org/10.1002/ejhf.3075

APA

Russo, G., Badano, L. P., Adamo, M., Alessandrini, H., Andreas, M., Braun, D., Connelly, K. A., Denti, P., Estevez-Loureiro, R., Fam, N., Gavazzoni, M., Hahn, R. T., Harr, C., Hausleiter, J., Himbert, D., Kalbacher, D., Ho, E., Latib, A., Lubos, E., ... Taramasso, M. (2023). Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry. EUR J HEART FAIL, 25(12), 2243-2251. https://doi.org/10.1002/ejhf.3075

Vancouver

Russo G, Badano LP, Adamo M, Alessandrini H, Andreas M, Braun D et al. Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry. EUR J HEART FAIL. 2023 Dec;25(12):2243-2251. https://doi.org/10.1002/ejhf.3075

Bibtex

@article{94756aee37ed4c269ea7b4d11816cb5f,
title = "Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry",
abstract = "AIM: Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER.METHODS AND RESULTS: Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction ≥50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR ≥3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75).CONCLUSIONS: In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR.",
author = "Giulio Russo and Badano, {Luigi P} and Marianna Adamo and Hannes Alessandrini and Martin Andreas and Daniel Braun and Connelly, {Kim A} and Paolo Denti and Rodrigo Estevez-Loureiro and Neil Fam and Mara Gavazzoni and Hahn, {Rebecca T} and Claudia Harr and Joerg Hausleiter and Dominique Himbert and Daniel Kalbacher and Edwin Ho and Azeem Latib and Edith Lubos and Sebastian Ludwig and Philipp Lurz and Vanessa Monivas and Georg Nickenig and Daniela Pedicino and Giovanni Pedrazzini and Alberto Pozzoli and {Pires Marafon}, Denise and Roberta Pastorino and Fabien Praz and Joseph Rodes-Cabau and Christian Besler and Joachim Schofer and Andrea Scotti and Kerstin Piayda and Horst Sievert and Tang, {Gilbert H L} and Holger Thiele and Florian Schlotter and {von Bardeleben}, {Ralph Stephan} and John Webb and Stephan Windecker and Martin Leon and Francesco Maisano and Marco Metra and Maurizio Taramasso",
note = "{\textcopyright} 2023 European Society of Cardiology.",
year = "2023",
month = dec,
doi = "10.1002/ejhf.3075",
language = "English",
volume = "25",
pages = "2243--2251",
journal = "EUR J HEART FAIL",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "12",

}

RIS

TY - JOUR

T1 - Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry

AU - Russo, Giulio

AU - Badano, Luigi P

AU - Adamo, Marianna

AU - Alessandrini, Hannes

AU - Andreas, Martin

AU - Braun, Daniel

AU - Connelly, Kim A

AU - Denti, Paolo

AU - Estevez-Loureiro, Rodrigo

AU - Fam, Neil

AU - Gavazzoni, Mara

AU - Hahn, Rebecca T

AU - Harr, Claudia

AU - Hausleiter, Joerg

AU - Himbert, Dominique

AU - Kalbacher, Daniel

AU - Ho, Edwin

AU - Latib, Azeem

AU - Lubos, Edith

AU - Ludwig, Sebastian

AU - Lurz, Philipp

AU - Monivas, Vanessa

AU - Nickenig, Georg

AU - Pedicino, Daniela

AU - Pedrazzini, Giovanni

AU - Pozzoli, Alberto

AU - Pires Marafon, Denise

AU - Pastorino, Roberta

AU - Praz, Fabien

AU - Rodes-Cabau, Joseph

AU - Besler, Christian

AU - Schofer, Joachim

AU - Scotti, Andrea

AU - Piayda, Kerstin

AU - Sievert, Horst

AU - Tang, Gilbert H L

AU - Thiele, Holger

AU - Schlotter, Florian

AU - von Bardeleben, Ralph Stephan

AU - Webb, John

AU - Windecker, Stephan

AU - Leon, Martin

AU - Maisano, Francesco

AU - Metra, Marco

AU - Taramasso, Maurizio

N1 - © 2023 European Society of Cardiology.

PY - 2023/12

Y1 - 2023/12

N2 - AIM: Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER.METHODS AND RESULTS: Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction ≥50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR ≥3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75).CONCLUSIONS: In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR.

AB - AIM: Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER.METHODS AND RESULTS: Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction ≥50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR ≥3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75).CONCLUSIONS: In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR.

U2 - 10.1002/ejhf.3075

DO - 10.1002/ejhf.3075

M3 - SCORING: Journal article

C2 - 37905381

VL - 25

SP - 2243

EP - 2251

JO - EUR J HEART FAIL

JF - EUR J HEART FAIL

SN - 1388-9842

IS - 12

ER -